Company research
Adicet Bio, Inc.
CIK 1720580Updated Sep 24, 2026
SecurityACET · NASDAQ · equity
Name history
resTORbio, Inc. · through Aug 21, 2020
ACET price & chart
Loading TradingView…
NASDAQ:ACET on TradingView ↗About the company
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G/A filing
4 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 192,355,000Source | 220,219,000Source | 207,295,000Source | 330,690,000Source |
| Property, Plant and Equipment, NetUSD | 16,532,000Source | 22,524,000Source | 26,777,000Source | 28,710,000Source |
| GoodwillUSD | — | — | 0Source | 19,462,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 38,918,000Source | 56,495,000Source | 159,711,000Source | 257,656,000Source |
| Assets, CurrentUSD | 160,926,000Source | 180,136,000Source | 162,272,000Source | 261,038,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,396,000Source | 3,833,000Source | 2,561,000Source | 3,382,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,927,000Source | 14,228,000Source | 17,424,000Source | 20,269,000Source |
| Other Assets, NoncurrentUSD | 76,000Source | 428,000Source | 822,000Source | 1,211,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 33,145,000Source | 33,610,000Source | 37,120,000Source | 38,352,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 10,000Source | 8,000Source | 4,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -614,697,000Source | -497,894,000Source | -380,772,000Source | -238,114,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 102,000Source | 16,000Source | — | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 159,210,000Source | 186,609,000Source | 170,175,000Source | 292,338,000Source |
| Additional Paid in Capital, Common StockUSD | 773,795,000Source | 684,479,000Source | 550,943,000Source | 530,448,000Source |
| Liabilities and EquityUSD | 192,355,000Source | 220,219,000Source | 207,295,000Source | 330,690,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 21,531,000Source | 19,392,000Source | 19,287,000Source | 19,707,000Source |
| Operating Lease, Liability, CurrentUSD | 2,837,000Source | 3,132,000Source | 3,221,000Source | 2,492,000Source |
| Accounts Payable, CurrentUSD | 4,739,000Source | 4,830,000Source | 2,625,000Source | 4,404,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,910,000Source | 14,102,000Source | 17,703,000Source | 18,531,000Source |
| Other Liabilities, NoncurrentUSD | 62,000Source | 116,000Source | 130,000Source | 114,000Source |
| Additional Financial Items | ||||
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,267,000Source | 22,233,000Source | 20,259,000Source | 17,126,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,029,000Source | 1,106,000Source | -1,683,000Source | 1,710,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -95,246,000Source | -92,378,000Source | -93,717,000Source | -44,765,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 2,393,000Source | -119,242,000Source | -4,464,000Source | -16,782,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,738,000Source | 1,118,000Source | 4,464,000Source | 16,782,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 104,000Source | 141,000Source | 150,000Source | 3,234,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 75,245,000Source | 111,307,000Source | 236,000Source | 41,509,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -17,608,000Source | -100,313,000Source | -97,945,000Source | -20,038,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 41,790,000Source | 59,398,000Source | 159,711,000Source | 257,656,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 14,267,000Source | 22,233,000Source | 20,259,000Source | 17,126,000Source |
| DepreciationUSD | 6,381,000Source | 6,468,000Source | — | — |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of AssetsUSD | -103,000Source | — | 4,000Source | -55,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | 200,000Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | 100,000Source |
| General and Administrative ExpenseUSD | 22,987,000Source | 28,292,000Source | 26,533,000Source | 26,295,000Source |
| GoodwillUSD | — | — | 0Source | 19,462,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 19,462,000Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Operating ExpensesUSD | 122,114,000Source | 127,615,000Source | 152,038,000Source | 97,541,000Source |
| Other Nonoperating Income (Expense)USD | -430,000Source | -217,000Source | -573,000Source | -919,000Source |
| Other Operating Income (Expense), NetUSD | 466,000Source | 221,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | 0Source | 19,266,000Source | 0Source | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 1,000Source | 195,000Source | 4,000Source | 1,315,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -122,114,000Source | -127,615,000Source | -152,038,000Source | -72,551,000Source |
| Other Nonoperating Income (Expense)USD | -430,000Source | -217,000Source | -573,000Source | -919,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Earnings Per Share, BasicUSD per share | -16.95Source | -1.33Source | -3.31Source | -1.7Source |
| Earnings Per Share, DilutedUSD per share | -16.95Source | -1.33Source | -3.31Source | -1.7Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 6,891,336Source | 87,866,435Source | 43,042,405Source | 41,080,286Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 6,891,336Source | 87,866,435Source | 43,042,405Source | 41,080,286Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 6,381,000Source | 6,468,000Source | 6,098,000Source | 2,575,000Source |
| General and Administrative ExpenseUSD | 22,987,000Source | 28,292,000Source | 26,533,000Source | 26,295,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 19,462,000Source | 0Source |
| Interest and Other IncomeUSD | 5,777,000Source | 10,714,000Source | 9,978,000Source | 3,760,000Source |
| Interest ExpenseUSD | 36,000Source | 4,000Source | 25,000Source | 80,000Source |
| Interest Income, OperatingUSD | 5,777,000Source | 10,714,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Operating ExpensesUSD | 122,114,000Source | 127,615,000Source | 152,038,000Source | 97,541,000Source |
| Other Operating Income (Expense), NetUSD | 466,000Source | 221,000Source | — | — |
| Research and Development ExpenseUSD | 99,127,000Source | 99,323,000Source | 106,043,000Source | 71,246,000Source |
Filing attachments
acet-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 acet-ex99_1.htm EX-99.1 September 2026 Investor Overview Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to ide…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-09-01
EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update Prula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeli…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with a minimum of 6 months follow-up, including 13 patients with at least 12 months of follow-up; topline results now anticipated in 3Q/2026 Productive…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates Clinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients with a minimum of six months follow-up U.S. Food and Drug Administration (FDA) interaction to inform potential pivotal trial design for prula-cel…
Read attachment ↗acet-ex4_1.htm · 8-K · 2026-04-28
EX-4.1 2 acet-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 Form of Pre-Funded Warrant ADICET BIO, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [_________] (subject to adjustment) Warrant No. [___] Original Issue Date: [___], 2026 Adicet Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the “Holder”) is entitled, subject t…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-03-12
EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 Achieved regulatory alignment with the FDA enabling outpatient dosing of prula-cel for lupus nephritis (LN) and systemic lupus erythematosus (SLE) …
Read attachment ↗